Healthcare provider profile · identity verified

Kerry Eugene Shaver, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · DENHAM SPRINGS, LA · NPI 1285805952

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kerry Eugene Shaver, M.D. received $18.37 in general payments during 2025 across 1 reported records.

Exact Sciences Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$18.37

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Exact Sciences Corporation Unresolved — no canonical attribution shown $18.37100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$18.371

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Cologuard Collection Kit
Normalized: cologuard collection kit
Device Exact Sciences Corporation $18.37 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium14374
Amlodipine BesylateAmlodipine Besylate13077
Levothyroxine SodiumLevothyroxine Sodium10454
Pantoprazole SodiumPantoprazole Sodium9756
GabapentinGabapentin8946
Metformin HclMetformin Hcl8547
OmeprazoleOmeprazole7742
Rosuvastatin CalciumRosuvastatin Calcium7237
LisinoprilLisinopril6440
Tamsulosin HclTamsulosin Hcl6329
Trazodone HclTrazodone Hcl6033
Albuterol Sulfate HfaAlbuterol Sulfate5731
FurosemideFurosemide5225
MeloxicamMeloxicam4727
Olmesartan MedoxomilOlmesartan Medoxomil4717
OzempicSemaglutide4720
CarvedilolCarvedilol4624
Escitalopram OxalateEscitalopram Oxalate4622
Duloxetine HclDuloxetine Hcl4517
Montelukast SodiumMontelukast Sodium4519
HydrochlorothiazideHydrochlorothiazide4430
Losartan PotassiumLosartan Potassium4224
Fluticasone PropionateFluticasone Propionate4124
Alendronate SodiumAlendronate Sodium4020
EzetimibeEzetimibe3920
Fluoxetine HclFluoxetine Hcl3819
JardianceEmpagliflozin3813
Metoprolol TartrateMetoprolol Tartrate3518
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide3320
AlprazolamAlprazolam3215
ClopidogrelClopidogrel Bisulfate3220
ClonazepamClonazepam31suppressed
Metoprolol SuccinateMetoprolol Succinate2918
SimvastatinSimvastatin2820
Oxybutynin Chloride ErOxybutynin Chloride26suppressed
Pravastatin SodiumPravastatin Sodium2620
Quetiapine FumarateQuetiapine Fumarate26suppressed
Memantine HclMemantine Hcl25suppressed
Sertraline HclSertraline Hcl2513
LinzessLinaclotide2211
Amitriptyline HclAmitriptyline Hcl21suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog2111
Meclizine HclMeclizine Hcl21suppressed
Metformin Hcl ErMetformin Hcl2011
PregabalinPregabalin20suppressed
TradjentaLinagliptin20suppressed
AllopurinolAllopurinol1912
FamotidineFamotidine19suppressed
FinasterideFinasteride19suppressed
Citalopram HbrCitalopram Hydrobromide1811
MupirocinMupirocin1813
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17suppressed
Hydroxyzine PamoateHydroxyzine Pamoate16suppressed
Ropinirole HclRopinirole Hcl16suppressed
Bupropion XlBupropion Hcl15suppressed
EliquisApixaban15suppressed
Glipizide ErGlipizide15suppressed
Hydroxyzine HclHydroxyzine Hcl15suppressed
Levocetirizine DihydrochlorideLevocetirizine Dihydrochloride15suppressed
Tizanidine HclTizanidine Hcl15suppressed
Tramadol HclTramadol Hcl1512
Cyclobenzaprine HclCyclobenzaprine Hcl14suppressed
MethocarbamolMethocarbamol1412
Oxybutynin ChlorideOxybutynin Chloride14suppressed
Varenicline TartrateVarenicline Tartrate14suppressed
Doxycycline HyclateDoxycycline Hyclate1313
Dropsafe Prep PadsAlcohol Antiseptic Pads13suppressed
FenofibrateFenofibrate Nanocrystallized13suppressed
IbuprofenIbuprofen1312
LovastatinLovastatin13suppressed
MounjaroTirzepatide13suppressed
Venlafaxine Hcl ErVenlafaxine Hcl13suppressed
AripiprazoleAripiprazole12suppressed
AtenololAtenolol12suppressed
Buspirone HclBuspirone Hcl12suppressed
Nifedipine ErNifedipine12suppressed
Potassium ChloridePotassium Chloride12suppressed
RybelsusSemaglutide12suppressed
XifaxanRifaximin12suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1111
Clindamycin HclClindamycin Hcl11suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11suppressed
Paroxetine HclParoxetine Hcl11suppressed
Pramipexole DihydrochloridePramipexole Di-Hcl11suppressed
Soliqua 100-33Insulin Glargine/Lixisenatide11suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $18.37 · 1 records Exact Sciences Corporation Cologuard Collection Kit
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error